What does a negative NASH (non‑alcoholic steatohepatitis) score indicate in a patient with hepatic steatosis on CT scan?

A Negative NASH Score with Hepatic Steatosis on CT Indicates Simple Steatosis (NAFL), Not Steatohepatitis

A negative NASH score in the presence of hepatic steatosis on CT scan indicates that the patient has nonalcoholic fatty liver (NAFL) rather than nonalcoholic steatohepatitis (NASH), meaning they have isolated steatosis without the hepatocellular injury (ballooning) and inflammation that define NASH. This distinction is clinically critical because NAFL carries a negligible risk of progression to cirrhosis, while NASH has substantially higher risk of advancing to end-stage liver disease, hepatocellular carcinoma, and liver-related mortality 1, 2.

Understanding the Diagnostic Framework

The NAFLD spectrum encompasses two distinct entities with dramatically different prognoses:

• NAFL (Simple Steatosis): ≥5% hepatic steatosis without hepatocellular injury (no ballooning), with or without mild inflammation. This represents the benign end of the spectrum 3, 4.

• NASH: ≥5% hepatic steatosis PLUS inflammation with hepatocyte injury (ballooning), with or without fibrosis. This is the progressive form 1, 5.

The NAFLD Activity Score (NAS) was designed as a research tool to measure histological changes in clinical trials, NOT as a diagnostic substitute for the pathologist's pattern-based diagnosis of NASH 6, 7. This is a critical distinction that is frequently misunderstood in clinical practice.

What Your Negative NASH Score Actually Means

When the NAS is <5 (commonly considered "negative"), this suggests:

• 68% negative predictive value that the patient does NOT have steatohepatitis when using NAS <5 as the threshold 6
• The patient likely has simple steatosis, steatosis with mild inflammation (but no ballooning), or borderline steatohepatitis 1
• 29% of patients with NAS ≤4 still had definite steatohepatitis on formal pathological diagnosis 7, highlighting why NAS thresholds should not replace pattern-based diagnosis

Critical Clinical Implications

Prognostic Significance

Patients with NAFL have excellent prognosis from a liver standpoint 8. The primary risks are:

• Future development of diabetes mellitus
• Cardiovascular events
• Arterial hypertension 1

However, liver-specific mortality risk is minimal compared to NASH patients who face progressive fibrosis, cirrhosis, and hepatocellular carcinoma 2.

The Imaging Limitation Problem

CT scan can reliably detect moderate-to-severe steatosis but CANNOT distinguish NASH from simple steatosis 1. This is a fundamental limitation of all imaging modalities including ultrasound, CT, and MRI. Clinical, biochemical, or imaging measures cannot differentiate NASH from steatosis 1.

Even advanced biomarkers like cytokeratin-18 fragments have only modest accuracy (66% sensitivity, 82% specificity) for diagnosing NASH 1.

What You Should Do Next

Risk Stratification Algorithm

1. Assess metabolic risk factors that predict progression:

   • Presence of metabolic syndrome components (≥2 increases risk substantially) 8, 9
   • Type 2 diabetes (strongest predictor of NASH and advanced fibrosis) 2
   • Obesity, hypertension, dyslipidemia 9

2. Calculate non-invasive fibrosis scores:

   • FIB-4 or NAFLD Fibrosis Score to assess for advanced fibrosis risk 8, 9
   • These have high negative predictive value for excluding advanced fibrosis 1

3. Consider liver biopsy if:

   • Patient has diabetes and/or metabolic syndrome (high NASH risk) 2
   • Elevated aminotransferases persist 9
   • AST > ALT ratio, thrombocytopenia, or hypoalbuminemia (suggesting cirrhosis) 2
   • Non-invasive scores suggest intermediate-to-high fibrosis risk 8

Management Approach

For confirmed NAFL (negative NASH score, no advanced fibrosis):

• Lifestyle modification is the cornerstone: 5-10% weight loss, aerobic exercise 3-5 times weekly 2
• Manage cardiovascular risk aggressively: This is the primary mortality risk in NAFL patients 1, 8
• No NASH-specific pharmacotherapy indicated: Vitamin E and pioglitazone are reserved for biopsy-proven NASH 2
• Statins and metformin are safe for their standard indications (dyslipidemia, diabetes) 2

Common Pitfalls to Avoid

1. Do not use NAS thresholds as diagnostic criteria for NASH: The score was designed for clinical trials, not diagnosis 6, 7. Pattern-based pathological diagnosis remains the gold standard 1.

2. Do not assume benign disease without fibrosis assessment: Some patients can progress from NAFL directly to advanced fibrosis 2. Always stratify fibrosis risk with non-invasive tests.

3. Do not ignore cardiovascular risk: Even with "simple" steatosis, these patients have significantly elevated cardiovascular mortality risk that requires aggressive management 1, 8.

4. Do not rely on imaging alone: CT showing steatosis tells you nothing about inflammation, ballooning, or fibrosis—the features that determine prognosis 1.